A Real-World Study of EkoSonic Endovascular System in Chinese Populations With Acute Pulmonary Embolism

Launched by BOSTON SCIENTIFIC CORPORATION · Feb 5, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the EkoSonic Endovascular System, a medical treatment for patients in China who have a condition called acute pulmonary embolism (a blockage in the lungs caused by blood clots). The goal of the study is to gather information about how well this treatment works in real-life situations, outside of a controlled research setting. It will involve patients who have had symptoms for less than 14 days and who have certain heart measurements that indicate a right ventricle enlargement.

To be eligible for the trial, patients must be between the ages of 65 and 74, and the healthcare provider must choose to use the EkoSonic system along with a specific medication called r-tPA to treat them. The study is not recruiting participants yet, but once it starts, those who qualify can expect to receive this treatment and contribute valuable information to help understand its effectiveness for others in similar situations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days).
• • 2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
• • 3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.
• Exclusion Criteria:
• • 1. The patients with acute symptomatic pulmonary embolism (Symptomatic duration \< 14 days).
• • 2. The right ventricle diameter to left ventricle diameter of end-diastolic dimension ratio ≥1 measured by echocardiographic image
• • 3. Investigator has selected the EkoSonicTM Endovascular System with r-tPA to treat patient.